The transgenic construct contains a mutant human MAPT (tauKQ) transgene with lysine-to-glutamine amino acid substitutions that recapitulate MAPT K274 and K281 acetylation under the control of the mouse prion protein, Prnp, gene promoter. The nucleotide substitutions are, respectively, A to C at position 820 and A to C at position 841. Founder line 286 has higher expression of the transgene than founder line 1. The transgene is expressed in hippocampus, cortex and cerebellum.